KR20060076136A - 향상된 생체이용율을 가진 액상 약제들의 경구적 조제형태들 - Google Patents

향상된 생체이용율을 가진 액상 약제들의 경구적 조제형태들 Download PDF

Info

Publication number
KR20060076136A
KR20060076136A KR1020047021307A KR20047021307A KR20060076136A KR 20060076136 A KR20060076136 A KR 20060076136A KR 1020047021307 A KR1020047021307 A KR 1020047021307A KR 20047021307 A KR20047021307 A KR 20047021307A KR 20060076136 A KR20060076136 A KR 20060076136A
Authority
KR
South Korea
Prior art keywords
nitrooxy
acid
methyl
ester
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020047021307A
Other languages
English (en)
Korean (ko)
Inventor
솔다토 피에로 델
기안카를로 산투스
Original Assignee
니콕스 에스. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콕스 에스. 에이. filed Critical 니콕스 에스. 에이.
Publication of KR20060076136A publication Critical patent/KR20060076136A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020047021307A 2002-06-25 2003-06-20 향상된 생체이용율을 가진 액상 약제들의 경구적 조제형태들 Ceased KR20060076136A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2002A001392 2002-06-25
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Publications (1)

Publication Number Publication Date
KR20060076136A true KR20060076136A (ko) 2006-07-04

Family

ID=11450079

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047021307A Ceased KR20060076136A (ko) 2002-06-25 2003-06-20 향상된 생체이용율을 가진 액상 약제들의 경구적 조제형태들

Country Status (23)

Country Link
US (1) US20060171969A1 (https=)
EP (1) EP1526839B1 (https=)
JP (1) JP2005530835A (https=)
KR (1) KR20060076136A (https=)
CN (1) CN1319518C (https=)
AT (1) ATE356612T1 (https=)
AU (1) AU2003246564B2 (https=)
CA (1) CA2491152A1 (https=)
DE (1) DE60312523T2 (https=)
DK (1) DK1526839T3 (https=)
ES (1) ES2285182T3 (https=)
HK (1) HK1080364B (https=)
IL (1) IL165601A0 (https=)
IT (1) ITMI20021392A1 (https=)
MX (1) MXPA04012852A (https=)
NO (1) NO20050347L (https=)
NZ (1) NZ537204A (https=)
PL (1) PL206599B1 (https=)
PT (1) PT1526839E (https=)
RU (1) RU2323003C2 (https=)
SI (1) SI1526839T1 (https=)
WO (1) WO2004000273A1 (https=)
ZA (1) ZA200410109B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149053A3 (en) * 2008-06-02 2010-05-14 Dr. Reddy's Laboratories Ltd. Naproxcinod process and solid dispersion

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
US20030148818A1 (en) * 2002-01-18 2003-08-07 Myrhum Mark C. Golf club woods with wood club head having a selectable center of gravity and a selectable shaft
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
WO2003103602A2 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
CA2491127A1 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
ES2285233T3 (es) 2002-12-20 2007-11-16 Niconovum Ab Un material en particulas que contiene nicotina y celulosa microcristalina fisicamente y quimicamente estable.
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
PL1879466T5 (pl) * 2005-03-04 2016-07-29 Dsm Ip Assets Bv Spożywcza cząsteczkowa kompozycja lipidowa
US20080260816A1 (en) * 2005-09-16 2008-10-23 Bengt Herslof Particulate Lipid Pharmaceutical Composition
US20080293781A1 (en) 2005-11-23 2008-11-27 Alberto Gasco Salicylic Acid Derivatives
EP2786749A1 (en) * 2006-02-03 2014-10-08 Nicox S.A. Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
US9402809B2 (en) 2006-03-16 2016-08-02 Niconovum Usa, Inc. Snuff composition
MX2009011493A (es) * 2007-04-25 2009-11-09 Teva Pharma Complejo de excipiente farmaceutico.
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
CN102964250A (zh) * 2012-11-19 2013-03-13 吉林大学 氟比洛芬丁香酚酯药用化合物及其制剂和制备方法
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
CN105188677A (zh) 2013-03-13 2015-12-23 特瑞斯制药股份有限公司 苯佐那酯调释固体片剂和胶囊剂
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US12520867B2 (en) 2019-12-09 2026-01-13 Nicoventures Trading Limited Buffered oral compositions
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
MX2022007085A (es) * 2019-12-09 2022-08-19 Nicoventures Trading Ltd Nanoemulsion para uso oral.
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
MX2023015529A (es) 2021-06-25 2024-03-05 Nicoventures Trading Ltd Productos orales y metodo de fabricacion.
IL312564A (en) 2021-11-05 2024-07-01 Cinclus Pharma Holding Ab Publ Polymorphs of the hydrochloride salt of linfarezan glurate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5266615A (en) * 1975-11-29 1977-06-02 Sawai Seiyaku Kk Manufacturing of solidified oily liquid substance
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
JPS58213073A (ja) * 1982-06-07 1983-12-10 Masatoshi Yamada 油状物質の固形化法
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
JP2000016934A (ja) * 1998-06-30 2000-01-18 Eisai Co Ltd テプレノンを含有した錠剤
EP2127642A3 (en) * 1998-08-13 2010-02-24 Cima Labs, Inc. Microemulsions as solid dosage forms for oral administration
EP1140027B1 (en) * 1998-12-23 2005-10-12 Alza Corporation Dosage forms comprising porous particles
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149053A3 (en) * 2008-06-02 2010-05-14 Dr. Reddy's Laboratories Ltd. Naproxcinod process and solid dispersion

Also Published As

Publication number Publication date
WO2004000273A1 (en) 2003-12-31
HK1080364A1 (en) 2006-04-28
ATE356612T1 (de) 2007-04-15
MXPA04012852A (es) 2005-06-08
RU2323003C2 (ru) 2008-04-27
EP1526839B1 (en) 2007-03-14
JP2005530835A (ja) 2005-10-13
ITMI20021392A1 (it) 2003-12-29
PL206599B1 (pl) 2010-08-31
SI1526839T1 (sl) 2007-08-31
NZ537204A (en) 2006-07-28
EP1526839A1 (en) 2005-05-04
PL374388A1 (en) 2005-10-17
CN1665486A (zh) 2005-09-07
HK1080364B (zh) 2008-02-01
US20060171969A1 (en) 2006-08-03
NO20050347L (no) 2005-01-21
ITMI20021392A0 (it) 2002-06-25
AU2003246564B2 (en) 2008-06-12
IL165601A0 (en) 2006-01-15
CN1319518C (zh) 2007-06-06
PT1526839E (pt) 2007-06-06
RU2004138554A (ru) 2005-08-27
ES2285182T3 (es) 2007-11-16
CA2491152A1 (en) 2003-12-31
DE60312523D1 (de) 2007-04-26
AU2003246564A1 (en) 2004-01-06
DE60312523T2 (de) 2008-01-10
ZA200410109B (en) 2005-09-02
DK1526839T3 (da) 2007-05-21

Similar Documents

Publication Publication Date Title
KR20060076136A (ko) 향상된 생체이용율을 가진 액상 약제들의 경구적 조제형태들
EP0330532B1 (fr) Nouvelle forme galénique du fénofibrate
TWI428333B (zh) 醫藥組合物
JP5137289B2 (ja) 安定な乳化組成物
JPH0548206B2 (https=)
KR910004571B1 (ko) 경구용 당뇨병치료 제제를 제조하는 방법
KR20020000760A (ko) 발데콕시브 조성물
WO2010033179A1 (en) Granulates, process for preparing them and pharmaceutical products containing them
EP2214637A1 (en) Stabilized pediatric suspension of carisbamate
JP5288791B2 (ja) 難水溶性物質含有微細化組成物
KR20050039732A (ko) 이부프로펜 결정의 형성 방법
JPH04360833A (ja) １，４−ジヒドロピリジン誘導体を含有する製剤
JP3048602B2 (ja) ポリプレニル系化合物を含有する医薬組成物およびその製造方法
US20090196919A1 (en) Oxcarbazepine dosage forms
US20110217369A1 (en) Fenofibrate compositions
WO2021006267A1 (ja) ピラゾール誘導体の塩及びピラゾール誘導体の製剤
JP5171143B2 (ja) 用時溶解型ビタミン製剤及びその製造方法
KR20250052834A (ko) 프란루카스트의 생체이용률이 개선된 약제학적 조성물 및 그 제조방법
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
JP2025530029A (ja) エダラボンの経口製剤およびその改良された製造方法
JPH0977663A (ja) フルタミド組成物
JPH02157222A (ja) 新規なプロブコール含有固形製剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20041227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080522

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100827

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100827

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I